Elsevier

Lung Cancer

Volume 92, February 2016, Pages 47-52
Lung Cancer

Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer

https://doi.org/10.1016/j.lungcan.2015.12.003Get rights and content

Highlights

  • We analyzed the impact of consolidation/tumor ratio (CTR) on the outcomes after SBRT for early lung cancer.

  • Local control rates were high for patients with a CTR < 1.

  • Disease-free survival rates were associated with the CTR.

  • CTR effectively predicts outcomes after SBRT.

Abstract

Purpose

We investigated whether the ratio of the maximum diameter of consolidation to the maximum tumor diameter (consolidation/tumor ratio, CTR) predicted the outcomes of patients who received stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC).

Methods and materials

Between 2005 and 2014, 237 patients with stage I NSCLC were treated with SBRT, receiving 48 Gy in 4 fractions. Of these patients, those who received pretreatment thin section computed tomography were selected for this analysis. The relationship between the CTR and outcomes (local control [LC], disease-free survival [DFS], and overall survival [OS]) was analyzed.

Results

One hundred and fifty-five patients were eligible. The median follow-up time was 34.7 months (range, 1.2–109.8). In the CTR < 0.5, CTR 0.5–<1, and CTR = 1 groups, 0, 2, and 12 patients experienced local recurrences, respectively. Three-year DFS and OS rates were 96.7% and 87.5% in the CTR < 0.5 group, 85.1% and 81.1% in the CTR 0.5–<1 group, and 63.3% and 70.1% in the CTR = 1 group, respectively. In multivariate analysis, CTR was the only significant predictor of DFS (P < 0.001).

Conclusion

The CTR effectively predicts DFS after SBRT in NSCLC patients.

Introduction

Stereotactic body radiotherapy (SBRT) is used to treat medically inoperable patients with stage I non-small cell lung cancer (NSCLC) and achieves good local control and survival rates. Previous studies have reported relationships between several factors, including tumor size [1], biologically effective dose (BED) [2], and operability [3], [4], and outcomes following SBRT.

Recently, associations between thin-section computed tomography (TSCT) findings and pathological characteristics have been reported. The Japan Clinical Oncology Group (JCOG) 0201 study [5] reported that the ratio of the maximum diameter of consolidation to the maximum tumor diameter (consolidation/tumor ratio, CTR) (Fig. 1), measured radiologically, correlated with pathological findings in clinical stage IA lung cancer patients. They found that a CTR < 0.5 corresponded well with pathological non-invasiveness (the specificity and sensitivity were 96.4% and 30.4%, respectively), although their predetermined criterion (the lower limit of the 95% confidence interval [CI] for a specificity of 97%) was not statistically confirmed. The cutoff value was also able to define patients with an excellent prognosis before surgery [6]. According to this study, 5-year overall and relapse-free survival rates for patients meeting this criterion were 96.7% and 95.9%, respectively. Based on these results, JCOG initiated a prospective study [7] evaluating the validity of sublobar resection for patients with stage IA NSCLC.

To the best of our knowledge, no studies have focused on the relationship between the CTR and outcomes following SBRT. Therefore, we retrospectively investigated the CTR’s ability to predict the outcomes of NSCLC patients who had received SBRT.

Section snippets

Patients

Between April 2005 and March 2014, 237 patients diagnosed clinically or pathologically with stage I NSCLC were treated with SBRT, receiving 48 Gy in 4 fractions. Regarding patients without a pathological diagnosis, our multidisciplinary tumor board had decided to treat them with SBRT by reviewing radiological findings and identifying characteristic findings and tumor growth on CT imaging and/or a characteristic maximum standardized uptake value (SUV max) on 18F-fluorodeoxyglucose positron

Baseline patient characteristics

Table 1 summarizes the clinical characteristics of the three groups. Regarding pathologically proven tumors, the pathological diagnosis of all tumors for patients in the CTR < 0.5 and CTR 0.5–<1 groups was adenocarcinoma. The median PTV D95 of the CTR < 0.5 group was 1.2–1.5 Gy lower than that of the other groups. Statistically significant differences in sex (P = 0.040), pathology (P < 0.001), SUV max (P < 0.0001), and PTV D95 (P = 0.001) were observed between the three groups. The other characteristics did

Discussion

Our study showed that the post-SBRT LC rate was high for patients with a CTR < 1; no patients in the CTR < 0.5 group developed local recurrence. To date, few clinical reports have examined the relationship between radiological tumor characteristics and outcomes after SBRT. Badiyan et al. [9]. reported that the 3-year local control rate was 100% for biopsy-proven or radiographically diagnosed bronchioloalveolar carcinoma, visualized as nodules with a GGO on CT. In a retrospective multicenter study

Conclusions

The CTR effectively predicts DFS after SBRT in NSCLC patients. Longer follow-up is required to determine whether local control rates for tumors with a low CTR remain excellent over the long term.

References (17)

There are more references available in the full text version of this article.

Cited by (33)

  • CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy

    2022, Clinical Lung Cancer
    Citation Excerpt :

    Nevertheless, no previous pathological studies have provided evidence to support these phenomena. SBRT has both drawbacks and advantages, although it has been associated with excellent outcomes.28-30 First, lobectomy and mediastinal lymph node dissection are the standard treatments for early-stage lung cancer.16

View all citing articles on Scopus
View full text